Cerity Partners LLC Grows Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Cerity Partners LLC raised its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 451.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 103,589 shares of the company's stock after acquiring an additional 84,804 shares during the quarter. Cerity Partners LLC's holdings in Dr. Reddy's Laboratories were worth $1,636,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its stake in Dr. Reddy's Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after purchasing an additional 1,507 shares during the last quarter. POM Investment Strategies LLC lifted its position in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after buying an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Dr. Reddy's Laboratories by 461.0% in the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after buying an additional 2,093 shares in the last quarter. Independence Bank of Kentucky grew its position in shares of Dr. Reddy's Laboratories by 400.0% in the 4th quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock valued at $44,000 after buying an additional 2,220 shares during the last quarter. Finally, Allworth Financial LP raised its stake in Dr. Reddy's Laboratories by 447.8% during the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company's stock worth $41,000 after acquiring an additional 2,230 shares in the last quarter. Hedge funds and other institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Performance

NYSE RDY traded up $0.25 during trading hours on Friday, hitting $13.69. The company had a trading volume of 2,412,404 shares, compared to its average volume of 1,443,151. The business has a 50 day moving average of $13.16 and a 200-day moving average of $14.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy's Laboratories Limited has a 1-year low of $12.26 and a 1-year high of $16.89. The company has a market cap of $11.42 billion, a PE ratio of 21.79 and a beta of 0.51.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities research analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.